12:14 EDT Krystal Biotech (KRYS) pauses enrollment in OPAL-1 Phase 1/2 trial
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges
- Krystal Biotech: Strong Financial Performance and Strategic Growth Initiatives Support Buy Rating
- Krystal Biotech Reports Strong Q2 2025 Results
- Krystal Biotech price target lowered to $166 from $176 at Citi
- Krystal Biotech’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating